rhFSH+rhLH
Phase 3Small molecule
rhFSH+rhLH is one of 7 small molecule programs targeting Ovarian Stimulation. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
6
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
10 competitors in Ovarian Stimulation
#DrugCompanyPhaseTrials
1Luveris
Merck & Co.Phase 3
Progestin
WWashington University School of Medicine
Phase 3
rhFSH+rhLH
FFundación Santiago Dexeus Font
Phase 3
Depo-Provera
Eli LillyPreclinical
Gynorest
SSolvay Pharmaceuticals
Preclinical
Trelstar
OOncoVerity, Inc.
Preclinical
Gonadotropin Releasing Hormone Antagonist
AAssiut University
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for rhFSH+rhLH. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- FFundación Santiago Dexeus Font